GAMMA Investing’s DiaMedica Therapeutics DMAC Stock Holding History

GAMMA Investing’s Portfolio DMAC Stock Details DMAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.52K	Buy	426 +223	+110%	+$1.56K	﹤0.01%	3783
2026 Q2	$1.43K	Sell	203 -164	-45%	-$1.01K	﹤0.01%	3794
2026 Q1	$2.48K	Buy	367 +265	+260%	+$2.1K	﹤0.01%	3593
2025 Q4	$812	Hold	102	–	–	﹤0.01%	3842
2025 Q3	$701	Buy	+102	New	+$553	﹤0.01%	3667

Other funds holding DMAC

Blue Trust Inc Alpharetta, Georgia $9.5B AUM 13.02% 1-Year Est. Return

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GWM

GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return

TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return

GAMMA Investing's DMAC Position: Q3 2026 in Review

GAMMA Investing increased its DiaMedica Therapeutics (DMAC) stake by 110% in Q3 2026, buying an estimated $1.56K and bringing the position to 426 shares worth $3.52K. The position accounts for ﹤0.01% of the portfolio, ranked #3783.

GAMMA Investing first reported a position in DMAC in Q3 2025 and has held it in 5 quarters since. 6 funds tracked by Wall St. Rank hold DMAC as of Q3 2026.

GAMMA Investing held 426 shares of DiaMedica Therapeutics worth $3.52K as of Q3 2026.
GAMMA Investing bought 223 DiaMedica Therapeutics shares in Q3 2026, an estimated $1.56K.
DiaMedica Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #3783 holding.
GAMMA Investing first reported a position in DiaMedica Therapeutics in Q3 2025 and has held it in 5 quarters since.
6 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.